JP2022544050A5 - - Google Patents

Info

Publication number
JP2022544050A5
JP2022544050A5 JP2022505553A JP2022505553A JP2022544050A5 JP 2022544050 A5 JP2022544050 A5 JP 2022544050A5 JP 2022505553 A JP2022505553 A JP 2022505553A JP 2022505553 A JP2022505553 A JP 2022505553A JP 2022544050 A5 JP2022544050 A5 JP 2022544050A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022505553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544050A (ja
JP7638955B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/105039 external-priority patent/WO2021018114A1/zh
Publication of JP2022544050A publication Critical patent/JP2022544050A/ja
Publication of JP2022544050A5 publication Critical patent/JP2022544050A5/ja
Priority to JP2025024929A priority Critical patent/JP7858104B2/ja
Application granted granted Critical
Publication of JP7638955B2 publication Critical patent/JP7638955B2/ja
Priority to JP2026073745A priority patent/JP2026126318A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022505553A 2019-07-30 2020-07-28 抗ヒトp40タンパク質ドメイン抗体及びその使用 Active JP7638955B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025024929A JP7858104B2 (ja) 2019-07-30 2025-02-19 抗ヒトp40タンパク質ドメイン抗体及びその使用
JP2026073745A JP2026126318A (ja) 2019-07-30 2026-04-27 抗ヒトp40タンパク質ドメイン抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910706137.1 2019-07-30
CN201910706137 2019-07-30
CN201911040745 2019-10-29
CN201911040745.X 2019-10-29
CN201911171754 2019-11-25
CN201911171754.2 2019-11-25
PCT/CN2020/105039 WO2021018114A1 (zh) 2019-07-30 2020-07-28 抗人p40蛋白域抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025024929A Division JP7858104B2 (ja) 2019-07-30 2025-02-19 抗ヒトp40タンパク質ドメイン抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2022544050A JP2022544050A (ja) 2022-10-17
JP2022544050A5 true JP2022544050A5 (cg-RX-API-DMAC7.html) 2023-08-08
JP7638955B2 JP7638955B2 (ja) 2025-03-04

Family

ID=73735954

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022505553A Active JP7638955B2 (ja) 2019-07-30 2020-07-28 抗ヒトp40タンパク質ドメイン抗体及びその使用
JP2025024929A Active JP7858104B2 (ja) 2019-07-30 2025-02-19 抗ヒトp40タンパク質ドメイン抗体及びその使用
JP2026073745A Pending JP2026126318A (ja) 2019-07-30 2026-04-27 抗ヒトp40タンパク質ドメイン抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025024929A Active JP7858104B2 (ja) 2019-07-30 2025-02-19 抗ヒトp40タンパク質ドメイン抗体及びその使用
JP2026073745A Pending JP2026126318A (ja) 2019-07-30 2026-04-27 抗ヒトp40タンパク質ドメイン抗体及びその使用

Country Status (13)

Country Link
US (2) US12595300B2 (cg-RX-API-DMAC7.html)
EP (2) EP4744731A3 (cg-RX-API-DMAC7.html)
JP (3) JP7638955B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038775A (cg-RX-API-DMAC7.html)
CN (1) CN112079922B (cg-RX-API-DMAC7.html)
AU (1) AU2020320910A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145909A1 (cg-RX-API-DMAC7.html)
IL (1) IL290167A (cg-RX-API-DMAC7.html)
MX (2) MX2022001305A (cg-RX-API-DMAC7.html)
PH (1) PH12022550223A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021018114A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202202380B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020320910A1 (en) 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
CN118620077B (zh) * 2024-08-13 2024-11-12 苏州百道医疗科技有限公司 一种抗p40重组兔单克隆抗体及其应用
WO2026062296A1 (en) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CN103145837A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
US20120189637A1 (en) * 2010-10-06 2012-07-26 Valdes Joaquin Mario Methods for treating psoriasis
TW201242976A (en) 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
PT2692865E (pt) * 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CN103275222B (zh) 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN109293777A (zh) 2015-11-13 2019-02-01 叶才果 双功能抗体及其用途
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
GB201720351D0 (en) 2017-12-06 2018-01-17 Iontas Ltd Selecting for developability in drug discovery
AU2020320910A1 (en) 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof

Similar Documents

Publication Publication Date Title
CN110050000B (zh) 含有TGF-β受体的融合蛋白及其医药用途
JP2021526022A5 (cg-RX-API-DMAC7.html)
US10662250B2 (en) Humanized monoclonal antibody specific to syndecan-1
CN112512550A (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
RU2019104980A (ru) Анти-icos антитела
KR20090088878A (ko) 신규한 항증식 항체
US11965037B2 (en) Anti-HER3 humanized monoclonal antibody
JP2025114620A5 (cg-RX-API-DMAC7.html)
JP2020522281A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2025026839A (ja) Muc18に特異的な抗体
JP2021524255A5 (cg-RX-API-DMAC7.html)
CN115819592A (zh) 靶向ror1的抗原结合蛋白
CN113906053A (zh) 抗cea抗体及其应用
CN119487079A (zh) 一种pvrig/tigit双特异性抗体药物组合物及其用途
AU2016318158A1 (en) Anti-survivin antibodies for cancer therapy
JP7072703B6 (ja) Axlタンパク質に結合する抗体
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
TW201840585A (zh) 用於白斑病的治療的抗人cxcr3抗體
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
JP7643752B2 (ja) 抗pd-l1抗体およびその用途
CN120554514A (zh) 一种靶向人的叶酸受体α的单克隆抗体
KR20260070438A (ko) Gprc5d 및 cd3에 특이적으로 결합하는 이중특이성 항체를 포함하는 약학적 조성물
EP4644422A1 (en) Anti-nkg2a antibody and use thereof